It is also noteworthy that the low frequency of BARD1 PVs (less than 1%) in HBOC patients contrasts sharply with the much higher frequencies of BRCA1 and BRCA2 PVs, reinforcing the view of BARD1 as a gene conferring a moderate to low risk for breast cancer [17]. This evidence concerns the gene BARD1 and breast cancer.